Millennium Management LLC Sells 83,369 Shares of Haemonetics Co. (NYSE:HAE)

Millennium Management LLC trimmed its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 33.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 162,307 shares of the medical instruments supplier's stock after selling 83,369 shares during the period. Millennium Management LLC owned 0.32% of Haemonetics worth $12,673,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Thrivent Financial for Lutherans lifted its stake in shares of Haemonetics by 14.9% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier's stock worth $98,716,000 after buying an additional 164,111 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Haemonetics by 1.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 992,229 shares of the medical instruments supplier's stock worth $77,470,000 after buying an additional 10,990 shares during the last quarter. Boston Trust Walden Corp lifted its stake in shares of Haemonetics by 13.1% in the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock worth $71,500,000 after buying an additional 106,114 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of Haemonetics by 0.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 801,049 shares of the medical instruments supplier's stock worth $62,802,000 after buying an additional 5,668 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its stake in shares of Haemonetics by 3.2% in the fourth quarter. Fisher Asset Management LLC now owns 711,774 shares of the medical instruments supplier's stock worth $55,575,000 after buying an additional 22,265 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on HAE. Bank of America cut shares of Haemonetics from a "neutral" rating to an "underperform" rating and reduced their price objective for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. Needham & Company LLC dropped their target price on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. JMP Securities reaffirmed a "market outperform" rating and set a $100.00 target price on shares of Haemonetics in a research report on Tuesday, May 20th. Wall Street Zen lowered shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Finally, Raymond James reaffirmed a "strong-buy" rating and set a $105.00 target price (down previously from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Haemonetics presently has a consensus rating of "Moderate Buy" and a consensus target price of $97.89.

Haemonetics Stock Performance

Haemonetics stock traded up $0.31 on Thursday, hitting $67.92. The company's stock had a trading volume of 133,708 shares, compared to its average volume of 814,003. The firm has a market cap of $3.26 billion, a P/E ratio of 26.74, a price-to-earnings-growth ratio of 1.11 and a beta of 0.32. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. The company has a fifty day moving average price of $63.29 and a 200-day moving average price of $70.70. Haemonetics Co. has a one year low of $55.30 and a one year high of $94.99.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.02. The firm had revenue of $330.60 million for the quarter, compared to analyst estimates of $329.38 million. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. The business's revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.90 EPS. On average, equities analysts anticipate that Haemonetics Co. will post 4.55 earnings per share for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.